Do Not Use Tamiflu (Oseltamivir) for Infants with COVID-19
Tamiflu (oseltamivir) should not be used to treat infants with COVID-19. Oseltamivir is a neuraminidase inhibitor specifically designed to treat influenza virus infections, and SARS-CoV-2 (the virus causing COVID-19) does not possess neuraminidase as a target enzyme 1.
Why Oseltamivir Does Not Work for COVID-19
Mechanism Mismatch
- Oseltamivir targets influenza neuraminidase, an enzyme critical for influenza virus replication and spread 1
- SARS-CoV-2 lacks neuraminidase entirely, making oseltamivir mechanistically irrelevant for COVID-19 treatment
- The drug "attacks the influenza virus and stops it from spreading inside your body" but has no such mechanism against coronaviruses 1
Limited and Conflicting Evidence
While some retrospective studies have suggested potential benefits of oseltamivir in COVID-19 patients 2, 3, these findings are:
- Based on observational data with significant confounding
- Not supported by biological plausibility
- Contradicted by other studies showing no benefit 4
- The proposed mechanisms (sympathetic nervous system modulation, immunomodulation) remain speculative and unproven 5
The WHO explicitly recommends against using oseltamivir for COVID-19 except in the context of clinical trials, given the lack of evidence for patient-important outcomes 6.
When Oseltamivir IS Appropriate for Infants
Influenza Treatment
Oseltamivir is FDA-approved and recommended for treating influenza in infants:
For term infants 0-8 months with influenza 7:
- Dose: 3 mg/kg per dose, twice daily for 5 days
- Can be used from birth (as young as 2 weeks) when benefits outweigh risks 7, 8
For infants 9-11 months with influenza 7:
- Dose: 3.5 mg/kg per dose, twice daily for 5 days
For preterm infants with influenza 7, 8:
- Dosing based on postmenstrual age (gestational age + chronological age):
- <38 weeks PMA: 1.0 mg/kg per dose, twice daily
- 38-40 weeks PMA: 1.5 mg/kg per dose, twice daily
40 weeks PMA: 3.0 mg/kg per dose, twice daily
- For extremely preterm infants (<28 weeks), consult pediatric infectious disease 7
Critical Distinction: Influenza vs COVID-19
- Use oseltamivir only when influenza is confirmed or strongly suspected based on clinical presentation during influenza season and/or positive testing 7
- Do not use oseltamivir for COVID-19, even if the infant has respiratory symptoms
- If co-infection with both influenza and COVID-19 is suspected, oseltamivir may be appropriate for the influenza component only
Common Clinical Pitfall
The most common error is prescribing oseltamivir for any respiratory viral illness in infants. Remember:
- Oseltamivir is specific for influenza only
- COVID-19 requires different management strategies
- Rapid influenza testing should guide treatment decisions when available
- During influenza season with compatible symptoms, empiric treatment may be reasonable while awaiting test results, but this does not apply to COVID-19 7
Safety Considerations for Infants
When oseltamivir IS used appropriately for influenza in infants:
- Common adverse effects include nausea, vomiting, and diarrhea (especially in children <1 year) 7
- Use appropriate measuring devices (3-mL or 5-mL oral syringe) for accurate dosing 7
- The oral suspension contains sorbitol, which may cause GI upset in infants with hereditary fructose intolerance 7, 1
- Monitor for adverse events, particularly in very young or preterm infants 9